Article: Intranasal immunization with inactivated SARS-CoV (SARS-associated coronavirus) induced local and serum antibodies in mice

File Download Links for fulltext
(May Require Subscription)
Supplementary
  • Basic View
  • Metadata View
  • XML View
TitleIntranasal immunization with inactivated SARS-CoV (SARS-associated coronavirus) induced local and serum antibodies in mice
AuthorsQu, D2
Zheng, B1
Yao, X2
Guan, Y1
Yuan, ZH2
Zhong, NS4
Lu, LW1
Xie, JP3
Wen, YM2
KeywordsInactivated vaccine
Intranasal immunization
SARS-CoV
Issue Date2005
PublisherElsevier Ltd. The Journal's web site is located at http://www.elsevier.com/locate/vaccine
CitationVaccine, 2005, v. 23 n. 7, p. 924-931 [How to Cite?]
DOI: http://dx.doi.org/10.1016/j.vaccine.2004.07.031
AbstractSARS-CoV (severe acute respiratory syndrome-associated coronavirus) strain GZ50 was partially purified and inactivated with 1:2000 formaldehyde. In cell culture the inactivated virus blocked the replication of live virus by decreasing the TCID 5.0 of the live virus 10 3.6 to 10 4.6 times. Inactivated GZ50 was used to immunize mice intranasally either alone, or after precipitation with polyethylene glycol (PEG), or with CpG, or CTB as an adjuvant. The titer of serum neutralizing antibodies was up to 1:640. In mice immunized with adjuvants or PEG precipitated GZ50, specific IgA was detected in tracheal-lung wash fluid by immunofluorescence. Though serum antibodies were detected, no anti-SARS-IgA could be detected in mice immunized only with inactivated GZ50. The roles of adjuvants in intranasal immunization with inactivated. SARS-CoV is discussed. © 2004 Elsevier Ltd. All rights reserved.
ISSN0264-410X
2011 Impact Factor: 3.766
2011 SCImago Journal Rankings: 0.369
DOIhttp://dx.doi.org/10.1016/j.vaccine.2004.07.031
ISI Accession Number IDWOS:000226326400011
ReferencesReferences in Scopus
DC Field
Value
dc.contributor.authorQu, D
dc.contributor.authorZheng, B
dc.contributor.authorYao, X
dc.contributor.authorGuan, Y
dc.contributor.authorYuan, ZH
dc.contributor.authorZhong, NS
dc.contributor.authorLu, LW
dc.contributor.authorXie, JP
dc.contributor.authorWen, YM
dc.date.accessioned2010-09-06T07:50:07Z
dc.date.available2010-09-06T07:50:07Z
dc.date.issued2005
dc.description.abstractSARS-CoV (severe acute respiratory syndrome-associated coronavirus) strain GZ50 was partially purified and inactivated with 1:2000 formaldehyde. In cell culture the inactivated virus blocked the replication of live virus by decreasing the TCID 5.0 of the live virus 10 3.6 to 10 4.6 times. Inactivated GZ50 was used to immunize mice intranasally either alone, or after precipitation with polyethylene glycol (PEG), or with CpG, or CTB as an adjuvant. The titer of serum neutralizing antibodies was up to 1:640. In mice immunized with adjuvants or PEG precipitated GZ50, specific IgA was detected in tracheal-lung wash fluid by immunofluorescence. Though serum antibodies were detected, no anti-SARS-IgA could be detected in mice immunized only with inactivated GZ50. The roles of adjuvants in intranasal immunization with inactivated. SARS-CoV is discussed. © 2004 Elsevier Ltd. All rights reserved.
dc.description.natureLink_to_subscribed_fulltext
dc.identifier.citationVaccine, 2005, v. 23 n. 7, p. 924-931 [How to Cite?]
DOI: http://dx.doi.org/10.1016/j.vaccine.2004.07.031
dc.identifier.doihttp://dx.doi.org/10.1016/j.vaccine.2004.07.031
dc.identifier.epage931
dc.identifier.hkuros99117
dc.identifier.isiWOS:000226326400011
dc.identifier.issn0264-410X
2011 Impact Factor: 3.766
2011 SCImago Journal Rankings: 0.369
dc.identifier.issue7
dc.identifier.openurl
dc.identifier.pmid15603894
dc.identifier.scopuseid_2-s2.0-10444272332
dc.identifier.spage924
dc.identifier.urihttp://hdl.handle.net/10722/79061
dc.identifier.volume23
dc.languageeng
dc.publisherElsevier Ltd. The Journal's web site is located at http://www.elsevier.com/locate/vaccine
dc.publisher.placeUnited Kingdom
dc.relation.ispartofVaccine
dc.relation.referencesReferences in Scopus
dc.rightsVaccine. Copyright © Elsevier Ltd.
dc.subject.meshAdministration, Intranasal
dc.subject.meshAnimals
dc.subject.meshAntibodies, Viral - biosynthesis - blood
dc.subject.meshCercopithecus aethiops
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshLung - immunology - metabolism
dc.subject.meshMale
dc.subject.meshMice
dc.subject.meshMice, Inbred BALB C
dc.subject.meshSARS Virus - immunology
dc.subject.meshVaccines, Inactivated - administration & dosage - immunology
dc.subject.meshVero Cells
dc.subject.meshViral Vaccines - administration & dosage - immunology
dc.subjectInactivated vaccine
dc.subjectIntranasal immunization
dc.subjectSARS-CoV
dc.titleIntranasal immunization with inactivated SARS-CoV (SARS-associated coronavirus) induced local and serum antibodies in mice
dc.typeArticle
Author Affiliations
  1. The University of Hong Kong
  2. Fudan University
  3. Guangzhou Children's Hospital
  4. Guangzhou Medical College